A federal judge has issued a preliminary injunction halting the Department of Health and Human Services’ (HHS) 340B Rebate Model Pilot Program, which was scheduled to take effect on January 1, 2026.

On July 31, the US Department of Health and Human Services’ (HHS) Health Resources and Services Administration (HRSA) announced the availability of a new pilot program altering how pharmaceutical ...

Jeff Davis, a partner in the Washington, D.C., law office of Bass, Berry & Sims, advises healthcare organizations on Medicare and Medicaid billing and reimbursement issues, with a special focus on the ...

Add Yahoo as a preferred source to see more of our stories on Google. A lawyer faces sanctions for citing fake cases created by a generative AI tool. (Getty Images) This story was originally published ...

Since 1992, the 340B drug discount program has entitled certain federal grantee clinics and hospitals (called “covered entities”) to purchase outpatient drugs at substantial discounts. The discounted ...

The Trump administration has approved eight drugmakers' rebate plans for a controversial 340B drug discount pilot program that kicks off Jan. 1. The 340B Rebate Model Pilot Program, unveiled this ...

While a federal judge squashed earlier plans for a 340B rebate pilot program, HHS appears poised to relaunch its attempts to transform the drug pricing program. Less than two weeks after the federal ...

If HHS’ 340B rebate model pilot proceeds as planned, more than 2,700 U.S. hospitals will collectively be saddled with approximately $400 million in operational costs and 11.2 million labor burden ...

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Federal regulators have greenlit eight drugmaker ...

The hospital lobby is asking federal officials to head off expanded data collection policies some drugmakers are implementing ...

The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug manufacturers to effectuate the 340B ceiling ...